Advocacy
We believe that patients need to participate in all conversations that relate to access to treatment, safety, or the quality of their care. At GHLF Australia, we raise the voice of people with chronic health conditions, carers and their community by focusing on various advocacy priorities at the community, state and federal level.
GHLF Australia regularly works with physician networks, national and state-level professional societies and other not-for-profit organisations and patient support groups to maximise the volume of our shared messages. This collaborative advocacy allows GHLF Australia to leverage the reach and impact of healthy living messages to effectively overcome barriers to care.
You can contribute to our advocacy efforts by responding to one of our surveys or becoming a GHLF Australia member.
Our submissions
2024
Victorian Government
Medicines Australia
National Health and Medical Research Council (NHMRC) and the Consumers Health Forum of Australia (CHF)
Australian Government Pharmaceutical Benefits Advisory Committee (PBAC)
- Support for the listing of tofacitinib 11mg extended-release tablet (Xeljanz® XR) on the PBS for rheumatoid arthritis and psoriatic arthritis
- Support for the expanded listing of bimekizumab (Bimzelx®) on the PBS for the treatment of severe psoriatic arthritis, ankylosing spondylitis and non-radiographic axial spondyloarthritis
- Support for the expanded listing of anifrolumab (Saphnelo®) on the PBS for the treatment of severe systemic lupus erythematosus
- Support for the listing of Respiratory Syncytial Virus Bivalent Vaccine (Abrysvo®) on the National Immunisation Program for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV)
Royal Australian College of Physicians
2023
Australian Government Pharmaceutical Benefits Advisory Committee (PBAC)
- Support for the listing of romosozumab (Evenity®) on the PBS for the treatment of osteoporosis
- Support for the listing of tofacitinib (Xeljanz®) on the PBS for the treatment of juvenile idiopathic arthritis
- Support for the expanded listing of apremilast (Otezla®) on the PBS for the treatment of severe chronic plaque psoriasis
2022
Australian Government Department of Health and Aged Care
- Comments on the revised 2022 National Medicines Policy Consultation Draft. Phase 3 (September 2022)
- Comments on the revised 2022 National Medicines Policy Consultation Draft. Phase 2 (The consultation process was paused before this was submitted.)
Australian Government Department of Health and Aged Care – Therapeutic Goods Administration (TGA)
Australian Government House of Representatives Standing Committee on Health, Aged Care and Sport
Australian National Audit Office (ANAO)
Australian Government Pharmaceutical Benefits Advisory Committee (PBAC)
- Support for the listing of the vaccine Vaxelis® to the National Immunisation Program
- Support for the listing of deucravacitinib (Sotyktu®) on the PBS for the treatment of severe chronic plaque psoriasis
2021
Australian Government Department of Health and Aged Care